ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Core Viewpoint - ARS Pharmaceuticals has entered into a co-promotion agreement with ALK-Abelló A/S to promote neffy, an epinephrine nasal spray, targeting pediatricians and enhancing access to this needle-free treatment for severe allergic reactions, particularly ahead of the back-to-school season [1][2][3] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and caregivers to protect against severe allergic reactions that could lead to anaphylaxis [1][17] - The company is commercializing neffy, the only approved needle-free treatment for Type I allergic reactions, including anaphylaxis, for patients aged 4 years and older who weigh at least 33 pounds [4][6][17] Partnership Details - The agreement allows ARS Pharma to recognize all U.S. revenue and maintain sole responsibility for U.S. commercialization activities, including marketing and distribution [2][5] - ALK will promote neffy to approximately 9,000 pediatricians, representing about 55% of all community-use epinephrine prescriptions in the U.S. [2][5] - The partnership includes performance-based payments for ALK based on exceeding specific market share thresholds, starting at 30% of net revenue above an initial threshold in the second year [5] Market Strategy - ARS Pharma plans to launch a direct-to-consumer campaign in May 2025, coinciding with the availability of a 1 mg dose for children over four years old [3] - The company anticipates broadening unrestricted commercial access for neffy over the summer, ensuring a smooth prescribing experience for patients and physicians [3] Financial Outlook - ARS Pharma expects its operating expenses to increase by approximately $3 million per quarter starting in Q3 2025, but this will not impact its cash flow for 2025 [3]